AGEN Agenus Inc.

3.04
+0.03  (+1%)
Previous Close 3.01
Open 3.03
Price To Book -3.49
Market Cap 408,146,035
Shares 134,258,564
Volume 4,587,728
Short Ratio
Av. Daily Volume 943,351

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 2019.
AGEN2034 and AGEN1884
Solid tumors
Phase 1 data due 2019.
AGEN1884 (anti-CTLA-4)
Solid cancers
Approval announced October 20, 2017.
Shingrix
Shingles
Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
AGEN2034 (anti-PD-1)
Cervical cancer
Phase 1 data due 2019.
AGEN1181 - 2nd gen CTLA
Advanced cancer